Prognostic value of the new IASLC/ATS/ERS classification of clinical XXXX .

@entity1 @entity66 @entity2735 @entity2 @entity1514 @entity420
OBJECTIVES: We analyzed and validated the prognostic utility of the new International Association for the Study of @entity2 (IASLC)/American @entity1514 Society (ATS)/European Respiratory Society (ERS) for clinical @entity2 ( @entity420 ) classification of @entity420 ( @entity420 ). METHODS: We retrospectively reviewed 347 @entity1 with clinical stage IA nonmucinous @entity420 , who had undergone complete resection. The histological subtype was classified according to the predominant subtype, as proposed by the new IASLC/ATS/ERS @entity420 classification. RESULTS: The histopathological subtypes, defined according to the new IASLC/ATS/ERS @entity420 classification, were @entity2735 ( @entity2735 ) in 56 @entity1 (16.1%), minimally invasive @entity420 (MIA) in 15 (4.3%), @entity420 in 109 (31.4%), papillary-predominant @entity420 in 70 (20.2%), acinar-predominant @entity420 in 61 (17.6%), solid-predominant @entity420 in 30 (8.6%), and micropapillary-predominant @entity420 in 6 (1.7%). The 5-year @entity66 ( @entity66 ) rate was 100% for both @entity2735 and MIA. All cases of recurrence involved invasive @entity420 . The 5-year @entity66 for @entity420 was 99.0%; acinar-predominant @entity420 , 82.4%; papillary-predominant @entity420 , 80.8%; solid-predominant @entity420 , 73.6%; and micropapillary-predominant @entity420 , 33.3%. The predominant subtype of @entity420 was significantly correlated with @entity66 (P<0.0001). Multivariate analysis indicated that the pathological stage was an independent predictor of @entity66 (P=0.031). Other independent predictors of increased risk of recurrence were the presence of vascular or lymphatic invasion (HR=4.96, P=0.001), and a pathological stage more advanced than IB (HR=2.87, P=0.010). The coincidence between the clinical stage and pathological stage was 79.8%. The stage migration was found in 53.3% of solid-predominat @entity420 and in 83.3% of micropapillary-predominant @entity420 . CONCLUSION: The new IASLC/ATS/ERS @entity420 classification has prognostic value in predicting the recurrence and survival of @entity1 with clinical stage IA @entity420 . The frequency of stage migration was found in more than half of solid and micropapillary predominant ADCs.
